UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Initial postoperative therapy for glioblastoma and anaplastic astrocytoma

Author
Tracy Batchelor, MD, MPH
Section Editors
Jay S Loeffler, MD
Patrick Y Wen, MD
Deputy Editor
April F Eichler, MD, MPH

INTRODUCTION

High-grade gliomas are malignant, rapidly progressive brain tumors that are divided into anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma) and glioblastoma based upon their histopathologic features [1]. (See "Classification and pathologic diagnosis of gliomas", section on 'Histopathologic and molecular classification'.)

Most high-grade gliomas are best managed with a combined modality approach, incorporating adjuvant postoperative radiation therapy and adjuvant chemotherapy following initial surgery. Postoperative chemotherapy is discussed in this topic.

Other topics that are covered separately include:

The diagnostic approach to patients with suspected brain tumors (see "Clinical presentation and diagnosis of brain tumors")

Initial surgical management of malignant gliomas (see "Clinical manifestations and initial surgical approach to patients with high-grade gliomas")

                       

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Sep 26 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303:1323.
  2. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359:1011.
  3. Huncharek M, Muscat J, Geschwind JF. Multi-drug versus single agent chemotherapy for high grade astrocytoma; results of a meta-analysis. Anticancer Res 1998; 18:4693.
  4. Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA 2015; 314:2535.
  5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987.
  6. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459.
  7. Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23:2372.
  8. Hart MG, Garside R, Rogers G, et al. Temozolomide for high grade glioma. Cochrane Database Syst Rev 2013; :CD007415.
  9. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  10. Kole AJ, Park HS, Yeboa DN, et al. Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme. Cancer 2016; 122:2364.
  11. Gerber DE, Grossman SA, Zeltzman M, et al. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 2007; 9:47.
  12. Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011; 17:5473.
  13. Huang J, DeWees TA, Badiyan SN, et al. Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. Int J Radiat Oncol Biol Phys 2015; 92:1000.
  14. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 2.2014. http://www.nccn.org (Accessed on November 06, 2014).
  15. Temodar (temozolomide) prescribing information. http://www.merck.com/product/usa/pi_circulars/t/temodar_capsules/temodar_pi.pdf (Accessed on February 11, 2013).
  16. Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs 2012; 23:1099.
  17. Goldbecker A, Tryc AB, Raab P, et al. Hepatic encephalopathy after treatment with temozolomide. J Neurooncol 2011; 103:163.
  18. Dixit S, Hingorani M, Afzal P, Campbell AP. Temozolomide induced liver injury. Acta Neurol Belg 2011; 111:249.
  19. Sarganas G, Orzechowski HD, Klimpel A, et al. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol 2012; 14:541.
  20. http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=temozolomide&x=0&y=0 (Accessed on June 16, 2014).
  21. Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000; 17:1284.
  22. Clark SW, Taylor J, Wang DL, et al. Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma. Neurology 2013; 81:93.
  23. Neyns B, Cordera S, Joosens E, Pouratian N. Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide. J Clin Oncol 2008; 26:4518.
  24. Villano JL, Collins CA, Manasanch EE, et al. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 2006; 7:436.
  25. Singhal N, Selva-Nayagam S, Brown MP. Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature. J Neurooncol 2007; 85:229.
  26. Jalali R, Singh P, Menon H, Gujral S. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. J Neurooncol 2007; 85:105.
  27. Morris EB, Kasow K, Reiss U, et al. Bone marrow transplantation for severe aplastic anemia secondary to temozolomide. J Neurooncol 2009; 91:237.
  28. Nagane M, Nozue K, Shimizu S, et al. Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. J Neurooncol 2009; 92:227.
  29. George BJ, Eichinger JB, Richard TJ. A rare case of aplastic anemia caused by temozolomide. South Med J 2009; 102:974.
  30. Kopecký J, Priester P, Slovácek L, et al. Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. Strahlenther Onkol 2010; 186:452.
  31. Oh J, Kutas GJ, Davey P, et al. Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme. Curr Oncol 2010; 17:124.
  32. Chamberlain MC, Raizer J. Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. J Neurooncol 2009; 93:229.
  33. Su YW, Chang MC, Chiang MF, Hsieh RK. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol 2005; 71:315.
  34. Noronha V, Berliner N, Ballen KK, et al. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol 2006; 8:280.
  35. Dufour C, Da Costa L, Auger N, et al. Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report. J Pediatr Hematol Oncol 2008; 30:857.
  36. Kushner BH, Laquaglia MP, Kramer K, et al. Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. Pediatr Blood Cancer 2008; 51:552.
  37. Kim SJ, Park TS, Lee ST, et al. Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Ann Clin Lab Sci 2009; 39:392.
  38. Momota H, Narita Y, Miyakita Y, Shibui S. Secondary hematological malignancies associated with temozolomide in patients with glioma. Neuro Oncol 2013; 15:1445.
  39. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013; 31:4085.
  40. Armstrong TS, Wefel JS, Wang M, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 2013; 31:4076.
  41. Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010; 28:4601.
  42. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012; 48:2192.
  43. Sampson JH. Alternating Electric Fields for the Treatment of Glioblastoma. JAMA 2015; 314:2511.
  44. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294:2203.
  45. Stupp R, Taillibert S, Kanner A, et al. Tumor treating fields (TTFields): A novel treatment moality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma - First report of the full dataset of the EF14 randomized phase III trial. J Clin Oncol 2015; 33 (suppl; abstr 2000).
  46. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004; 64:3288.
  47. Kirson ED, Dbalý V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 2007; 104:10152.
  48. Bernard-Arnoux F, Lamure M, Ducray F, et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 2016; 18:1129.
  49. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5:79.
  50. Dixit S, Hingorani M, Achawal S, Scott I. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without previous gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas: in regard to Noel et al. (Int J Radiat Oncol Biol Phys 2011; DOI: 10.1016/j.ijrobp.2010.11.073). Int J Radiat Oncol Biol Phys 2011; 81:1593.
  51. Pallud J, Audureau E, Noel G, et al. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. Neuro Oncol 2015; 17:1609.
  52. Duntze J, Litré CF, Eap C, et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann Surg Oncol 2013; 20:2065.
  53. Burri SH, Prabhu RS, Sumrall AL, et al. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial. J Neurooncol 2015; 123:259.
  54. Weber EL, Goebel EA. Cerebral edema associated with Gliadel wafers: two case studies. Neuro Oncol 2005; 7:84.
  55. Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 2008; 24:3239.
  56. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29:142.
  57. Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011; 17:4119.
  58. Omuro A, Beal K, Gutin P, et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res 2014; 20:5023.
  59. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370:709.
  60. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370:699.
  61. Taphoorn MJ, Henriksson R, Bottomley A, et al. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. J Clin Oncol 2015; 33:2166.
  62. Khasraw M, Ameratunga MS, Grant R, et al. Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev 2014; :CD008218.
  63. Herrlinger U, Schäfer N, Steinbach JP, et al. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 2016; 34:1611.
  64. Zarnett OJ, Sahgal A, Gosio J, et al. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis. JAMA Neurol 2015; 72:589.
  65. WHO Classification of Tumours of the Central Nervous System, Revised 4th Edition, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.
  66. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27:5874.
  67. Brandes AA, Nicolardi L, Tosoni A, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 2006; 8:253.
  68. van den Bent MJ, Erridge S, Vogelbaum MA, et al. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. J Clin Oncol 2016; 34 (suppl):abstract LBA2000.
  69. Juratli TA, Lautenschläger T, Geiger KD, et al. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients. J Neurooncol 2015; 124:197.
  70. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31:344.
  71. Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014; 32:783.
  72. Shin JY, Diaz AZ. Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy. J Neurooncol 2016; 129:557.
  73. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013; 81:1515.
  74. Wing W, Roth P, Wiestler B, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide (abstract). J Clin Oncol 2015; 33:suppl; abstr 2001.
  75. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277.
  76. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963.